Only 57.3% of patients in the CagriSema trial reached the highest dose, with Novo providing no explanation for the low figure. A trial participant lost 18% of her weight but reported severe side ...

With its Q4 2024 results on Wednesday, Novo Nordisk (NVO) announced a new Phase 3 trial to test its highly-anticipated weight loss therapy, CagriSema, after a December readout failed to meet ...

LONDON/COPENHAGEN, Feb 5 (Reuters) - Novo Nordisk defended its next-generation obesity drug candidate CagriSema on Wednesday following late-stage trial data published in December that disappointed ...

Novo Nordisk said it plans to file for the first regulatory approval for its weight-loss drug CagriSema during the first quarter of 2026. Novo Nordisk's (NVO) U.S.-listed shares rose 5% in ...

LONDON, Jan 30 (Reuters) - Novo Nordisk (NOVOb.CO), opens new tab said on Thursday it has not yet posted details about a new trial of its experimental next-generation obesity drug CagriSema ...

LONDON/SAN FRANCISCO (Reuters) - Novo Nordisk (NVO) is under pressure from investors for more information about its next-generation obesity drug candidate CagriSema amid a lack of clarity over ...